Laurus Labs

Laurus joins ₹1 trillion market cap club as stock zooms 120% in 1 year

In the past month, Laurus Labs outperformed the market by surging 22 per cent, as compared to 2.1 per cent rise in the Nifty Midcap 50 index.

Stocks to buy: Hero MotoCorp among 3 stock ideas by MOFSL

Motilal Oswal's Chandan Taparia recommends Hero MotoCorp, Siemens, and Laurus Labs as technical buy ideas, citing bullish chart patterns, breakout formations, and strong sectoral momentum.

Healthcare up for 4th straight month; Divis, Laurus, Torrent at new highs

The BSE Healthcare hit a new high of 51,108 on Friday, rallying 3.7% in July. The index has surged 22% since April 2026.

Sun Pharma, TVS Motor, Nestle, Divis among 11 BSE 500 stocks at new highs

Among others, Manappuram Finance, Marico, Radico Khaitan, Redington, Welspun Corp, Laurus Labs and Sai Life Sciences also touched respective all-time highs in trade on Thursday.

Laurus Labs extends rally, up 97% from Feb low; tops Dr Reddy's market-cap

Laurus Labs quoted higher for the fourth straight day, surging 15% in this period after delivering record quarterly revenue with expanded profitability and continued portfolio transformation.

Laurus Labs rallies 4%, up 55% in 5 months; brokerages see more upside

The stock price of Laurus Labs hit a new high of ₹1,662.45 in intra-day deals on Monday; the stock has zoomed 176% in the past 14 months from levels of ₹601.75 on May 27, 2025.

Laurus Labs stock jumps 2%, hits new high on 125% surge in Q1 profit

Laurus Labs on Friday reported a 124.7% YoY surge in Q1 consolidated net profit at ₹361.99 crore, backed by 28.8% growth in total income. The stock has nearly doubled in the last one year.

Pharma index surges 2%; Torrent, Mankind, Cipla, Aurobindo soar up to 5%

Pharma stocks: RPG Life, Thyrocare, Hester Biosciences, Rubicon Research, IOL Chemicals, Emcure and Suven Life from the BSE Healthcare index rallied between 4% and 8% on Monday.

Laurus Labs zooms 53% in Q1FY27; logs sharpest quarterly rally in 5 years

Sustained clinical and commercial contracting across technologies and sites driving good growth outlook for CDMO business, the company said.

Nifty Pharma index up 2%; Dr Reddy's, Ajanta, Ipca, Cipla surge up to 5%

In the past seven trading days, the Nifty Pharma index outperformed the market by soaring 5.4 per cent, as compared to 0.1 per cent decline in the Nifty 50.

Nifty Pharma extends rally, up 2%; Piramal Pharma, Laurus gain up to 10%

Analysts said that a combination of defensive buying, strong earnings visibility, export tailwinds, and sector rotation is driving the rally in pharma stocks.

Sai Life, Laurus Labs hit new highs; stocks rally up to 40% in 6 months

Sai's management reiterated long-term guidance of 15-20 per cent revenue CAGR with 28-30 per cent steady state EBITDA margin over the next two to three years.

Nifty Midcap 100 index hits record high; Adani Total Gas surges 11%

In the past one month, the Nifty Midcap 100 index outperformed the market by gaining 3.4 per cent, as compared to 0.1 per cent decline in the Nifty 50.

CDMO stocks in focus: Laurus Labs hits new high; Sai Life Sciences gains 2%

In the past one month, Laurus Labs and Sai Life shares have surged 18 per cent and 15 per cent, respectively. In comparison, the BSE Sensex has slipped 4.2 per cent.

Marico, Nestle, Laurus, Grasim and 15 others from Nifty 500 hit new highs

Vijaya Diagnostic Centre was quoting higher for the eight straight trading day, soaring 25 per cent during the period.

Laurus, Sai Life Sciences up 3% in weak market; what's driving CDMO stocks?

In the past one month, Laurus (up 14 per cent) and Sai Life (up 15 per cent) have outperformed the market by soaring up to 15 per cent

Nifty Pharma hits 52-wk high; Wockhardt up 15%, Laurus, Lupin at new peaks

The Nifty Pharma index was quoting higher for the fifth straight trading day, surging 3.8 per cent during the period, as against 0.37 per cent gain in Nifty 50.

Laurus Labs rallies 6%, hits record high post Q4 results; brokerages upbeat

Laurus Labs is now getting the benefit of the same as the CDMO quarterly run rate has gone up from ₹220-250 crore to ₹450-500 crore in two years, believe analysts.

Nifty Pharma index soars 3%; Dr Reddy's, Piramal Pharma rally up to 9%

Glenmark Pharma, Cipla, Wockhardt, Mankind Pharma, Lupin, Zydus Life, Laurus, Ipca Labs, Divis Labs, Strides Pharma and Onesource were up in the range of 3% to 6%.

Trading guide: Nifty eyes 23,200; BSE, Laurus Labs, Cipla on analyst radar

Stocks to buy: Ajit Mishra of Religare Broking recommends buying BSE and Laurus Labs; also suggests Nifty trading strategy